Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib and Avelumab in Recurrent/Metastatic ACC
NCT03990571Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib and avelumab in adenoid cystic carcinoma (ACC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate up to 33 months. Started Jul 2019; status: completed.
02
Drugs
axitinibavelumab
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT03990571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990571.